Yes, my theory is similar to yours although it may be only wishful thinking. The recent management changes have been caused by an investor with deep pockets who sees the potential of ECTE. The amount of money needed to keep ECTE afloat is chump change to most pharmaceutical companies and the risk/reward ratio is attractive. It might also explain why ECTE and Scott Hollander in particular have ignored us because they knew they were short-timers.
If there is any merit to my theory, it will be reflected in the share price within the next couple of weeks.
News 
Market Data 
Discover 
